Exclusive Summary

• - EU27 registrations provide ready-to-go compliance and quality for rapid multi-country distribution.
• - Fully off-patent worldwide with >10 years of generic presence, enabling immediate entry and channel expansion.
• - The 250 mg strength fits uncomplicated UTI regimens and renal dose adjustments, and supports flexible dosing in MDR-TB programs.
• - Targets high-burden indications (≈150M UTI cases/year, ≈2.6M LRI deaths/year, 0.41–0.45M MDR/RR-TB cases/year) with highly bioavailable oral therapy suitable for outpatient and step-down use.
• - Prices typically 80–90% below originator and often lower than moxifloxacin, supporting tender competitiveness and out-of-pocket affordability.